Literature DB >> 17822346

Risperidone-induced enuresis in two children with autistic disorder.

Sabri Hergüner1, Nahit Motavalli Mukaddes.   

Abstract

INTRODUCTION: Risperidone appears to be effective in treating behavioral problems in children with autistic disorder. Although increased appetite, weight gain, and sedation are among the most common side effects, risperidone-induced enuresis is rarely reported.
METHOD: We will present two cases with risperidone-induced enuresis, and discuss our findings in the context of current literature.
RESULTS: Two children aged 11 and 10 years, diagnosed with autism and mental retardation, have developed new-onset diurnal and nocturnal enuresis respectively on their first and second weeks of risperidone monotherapy (1.5 and 1 mg/day). They did not experience sedation, and their medical history and workup were unremarkable. As enuresis did not resolve spontaneously, we decided to substitute risperidone with olanzapine. Enuresis ceased rapidly after discontinuation of risperidone with no emergence when patients were treated with olanzapine 5 mg/day for a period of 6 months and 1 year, respectively. DISCUSSION: Although the pathophysiology of antipsychotic-induced enuresis remains unclear, a number of mechanisms including alpha(1)-adrenergic blockade, dopamine blockade, and antimuscarinic effects has been proposed. Olanzapine has lower alpha(1)-adrenergic and dopaminergic blockade properties, thus changing risperidone to olanzapine may be an alternative modality in risperidone-induced enuresis when antipsychotic treatment is crucial. Clinicians should be more vigilant about screening for this side effect, especially in younger population with developmental disabilities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822346     DOI: 10.1089/cap.2006.0056

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  3 in total

1.  Optimising the management of children with concomitant bladder dysfunction and behavioural disorders.

Authors:  Dilharan D Eliezer; Christopher Lam; Angela Smith; John Mithran Coomarasamy; Naeem Samnakay; Malcolm R Starkey; Aniruddh V Deshpande
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-06-29       Impact factor: 5.349

2.  Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.

Authors:  Michael Aman; Mallikarjuna Rettiganti; Haikady N Nagaraja; Jill A Hollway; James McCracken; Christopher J McDougle; Elaine Tierney; Lawrence Scahill; L Eugene Arnold; Jessica Hellings; David J Posey; Naomi B Swiezy; Jaswinder Ghuman; Marco Grados; Bhavik Shah; Benedetto Vitiello
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-08       Impact factor: 2.576

3.  Risperidone-induced Enuresis in a 12-year-old Child.

Authors:  Reetika Dikshit; Sagar Karia; Avinash De Sousa
Journal:  J Neurosci Rural Pract       Date:  2017 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.